Advertisement

Topics

Genmab A/S Company Profile

22:47 EDT 24th September 2017 | BioPortfolio

Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999 and is publicly traded on the NASDAQ OMX Copenhagen. Genmab employs approximately 180 people with its headquarters and clinical development team in Denmark, research and development laboratories in The Netherlands and administrative functions in the United States.The company’s first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab. Ofatumumab is marketed under a co-development and collaboration agreement with GlaxoSmithKline and has been launched in 24 countries, as of September 2012. In addition to ofatumumab, Genmab is building a deep pipeline of clinical and pre-clinical antibody products to treat cancer and for other diseases where there is an unmet medical need.Genmab uses both validated and next generation proprietary antibody technologies to provide the company with a steady stream of fully human antibody product candidates. These innovative product candidates, as well as the technologies themselves, are a key focus of Genmab’s strategy and interest in them has enabled the company to form alliances with top tier pharmaceutical and biotechnology companies.

Location

Bredgade 23A, 3rd floor
Copenhagen K
DK-1260
Denmark

Contact

Phone: +45 7020 2728
Fax: +45 70 20 27 49
Email: info@nl.genmab.com


News Articles [58 Associated News Articles listed on BioPortfolio]

Genmab A/S: Genmab to Present at Morgan Stanley 15th Annual Global Healthcare Conference

Media ReleaseCopenhagen, Denmark; September 5, 2017 - Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will give a company update at the Morgan Stanley 15...

Genmab A/S: Genmab to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

Media ReleaseCopenhagen, Denmark; May 30, 2017 - Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the Goldman Sachs 38th ...

Genmab A/S: Grant of Restricted Stock Units and Warrants to Genmab employees

Company AnnouncementCopenhagen, Denmark; June 8, 2017 - Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 1,697 restricted stock units and 5,224...

Darzalex drives Genmab growth but profits miss

Danish biotech firm Genmab dwarfed its 2016 sales with both its half-year and quarterly figures, which…

Genmab A/S: Genmab Announces Financial Results for the First Quarter of 2017

May 10, 2017; Copenhagen, Denmark; Interim Report for the First Quarter of 2017Highlights -- USD 255 million in net sales of DARZALEX® (daratumumab); resulting in royalty income of DKK 211 million .....

Phase III Success for Janssen and Genmab with Frontline Myeloma Antibody

Results from a Phase III study with Janssen’s blockbuster daratumumab could lead to its approval as a first-line treatment for patients with multiple myeloma.  Danish Genmab has announced today...

Genmab A/S: Genmab Announces Financial Results for the First Half of 2017

August 9, 2017; Copenhagen, Denmark;Interim Report for the First Half of 2017Highlights -- USD 554 million in net sales of DARZALEX® (daratumumab); resulting in royalty income of DKK 454 million --.....

Genmab A/S: Genmab Announces Plans for New Studies of Daratumumab

Company Announcement -- 3 new Phase III studies of daratumumab planned in multiple myeloma and amyloidosis -- Studies planned to start between second half 2017 and first quarter 2018Copenhagen, Den...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Genmab Inc.

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat c...

Genmab A/S

Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Den...

TenX Biopharma, Inc.

TenX Biopharma, Inc., is a biopharmaceutical company focused on late stage development and commercialization of novel monoclonal antibody-based cancer therapies. TenX Biopharma acquired global rights ...

More Information about "Genmab A/S" on BioPortfolio

We have published hundreds of Genmab A/S news stories on BioPortfolio along with dozens of Genmab A/S Clinical Trials and PubMed Articles about Genmab A/S for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genmab A/S Companies in our database. You can also find out about relevant Genmab A/S Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record